Redmile Group, LLC Charles River Laboratories International, Inc. Transaction History

Redmile Group, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$164.52 - $238.84 $4.54 Million - $6.58 Million	-27,569 Reduced 24.11%	86,782 $20.5 Million
Q2 2023 Aug 14, 2023	SELL	$183.71 - $210.25 $179,484 - $205,414	-977 Reduced 0.85%	114,351 $24 Million
Q1 2023 May 15, 2023	BUY	$191.89 - $259.92 $22.1 Million - $30 Million	115,328 New	115,328 $23.3 Million
Q3 2021 Nov 15, 2021	SELL	$372.64 - $458.3 $40.4 Million - $49.7 Million	-108,374 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$294.17 - $371.65 $17.2 Million - $21.7 Million	-58,305 Reduced 34.98%	108,374 $40.1 Million
Q1 2021 May 17, 2021	BUY	$249.67 - $299.48 $41.6 Million - $49.9 Million	166,679 New	166,679 $48.3 Million

695

52.2M

259K

463K

Ticker CRL
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 50,863,300
Market Cap $9.64B
Description
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.